Royce & Associates LP Paratek Pharmaceuticals, Inc. Transaction History

Royce & Associates LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 06, 2020	SELL	$2.93 - $4.5 $863,764 - $1.33 Million	-294,800 Closed	0 $0
Q3 2019 Nov 13, 2019	BUY	$3.08 - $5.76 $175,868 - $328,896	57,100 Added 24.02%	294,800 $1.27 Million
Q2 2019 Aug 12, 2019	SELL	$3.47 - $6.32 $277,600 - $505,600	-80,000 Reduced 25.18%	237,700 $948,000
Q4 2018 Feb 11, 2019	SELL	$4.8 - $11.6 $368,011 - $889,360	-76,669 Reduced 19.44%	317,700 $1.63 Million
Q3 2018 Nov 13, 2018	SELL	$9.05 - $10.95 $167,425 - $202,575	-18,500 Reduced 4.48%	394,369 $3.83 Million
Q2 2018 Aug 09, 2018	BUY	$10.2 - $13.9 $236,639 - $322,480	23,200 Added 5.95%	412,869 $4.21 Million
Q1 2018 May 14, 2018	BUY	$12.65 - $18.85 $371,910 - $554,190	29,400 Added 8.16%	389,669 $5.07 Million
Q4 2017 Feb 09, 2018	BUY	$17.45 - $25.6 $1.17 Million - $1.72 Million	67,069 Added 22.87%	360,269 $6.45 Million
Q3 2017 Nov 13, 2017	BUY	$18.9 - $28.2 $194,669 - $290,460	10,300 Added 3.64%	293,200 $7.36 Million
Q2 2017 Aug 07, 2017	BUY	N/A	282,900	282,900 $6.82 Million

1.54M

Ticker PRTK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,862,500
Description
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectru...

Get notified when there are updates to the investment portfolio of Royce & Associates LP, based on Form 13F filings with the SEC.

Stay updated on Royce & Associates LP with notifications on news.